Persistent COVID-19 in immunocompromised patients-Israeli society of infectious diseases consensus statement on diagnosis and management.

Suzy E MeijerYael ParanAna BelkinRonen Ben-AmiYasmin MaorLior NesherKhetam HusseinGalia RahavTal Brosh-Nissimov

Published in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2024)

To reduce the risk of resistance and improve outcomes, we suggest treating pCOVID with a combination of antibody-based therapy and two antiviral drugs for duration of 5-10 days. Immunomodulatory therapy can be added in patients with an inflammatory clinical picture. In cases of treatment failure or relapse, prolonged antiviral treatment can be considered. For the prevention of pCOVID, we suggest active and passive vaccination and early initiation of treatment for acute COVID-19. Additional research on pCOVID treatment is urgently needed.

Keyphrases

coronavirus disease
sars cov
infectious diseases
type diabetes
stem cells
adipose tissue
oxidative stress
bone marrow
skeletal muscle
combination therapy
insulin resistance
acute respiratory distress syndrome
respiratory failure
mesenchymal stem cells
mechanical ventilation
aortic dissection